(CPRX) Catalyst Pharmaceuticals - Ratings and Ratios

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for rare diseases in the United States. Its product portfolio includes Firdapse, the first FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS); Fycompa, a novel non-competitive AMPA receptor antagonist for focal onset seizures and tonic-clonic seizures; Ruzurgi, specifically designed for pediatric LEMS patients; and AGAMREE, a corticosteroid addressing Duchenne muscular dystrophy. The company has strategic partnerships with BioMarin Pharmaceutical Inc. and Endo Ventures Limited for the development of generic Sabril tablets. Founded in 2002, Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida.

Based on the provided data, the 3-month forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) suggests potential growth. Technically, the stock is trading above its 20, 50, and 200-day moving averages, indicating bullish momentum. The ATR of 1.10 signals manageable volatility. Fundamentally, with a forward P/E of 13.40 and an ROE of 22.52%, the company shows strong earnings potential. However, the P/S ratio of 5.82 may indicate a premium valuation relative to its revenue. Overall, the stock is poised for growth, supported by solid earnings expectations and stable volatility.